Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer.
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D054598:Blue Cross Blue Shield Insurance Plans; D015331:Cohort Studies; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics*; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000378:metabolism / Q000633:toxicity*; D005820:Genetic Testing; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D013673:Technology Assessment, Biomedical; D013940:Thymidylate Synthase / Q000235:genetics*; D014481:United States; D014486:United States Food and Drug Administration
D000964:Antimetabolites, Antineoplastic; D042943:Dihydrouracil Dehydrogenase (NADP); D013940:Thymidylate Synthase; D005472:Fluorouracil